PT  - JOURNAL ARTICLE
AU  - Parry, Nicola
ED  - Hurvitz, Sara A.
TI  - No Survival Benefit When Adding Everolimus to Trastuzumab and Paclitaxel in Advanced HER2-Positive BC
DP  - 2014  01
TA  - MD Conference Express
PG  - 11--12
VI  - 14
IP  - 56
4099  - http://mdc.sagepub.com/content/14/56/11.short
4100  - http://mdc.sagepub.com/content/14/56/11.full
AB  - The BOLERO-1 phase 3 clinical trial demonstrated that adding everolimus to weekly trastuzumab and paclitaxel, as first-line therapy, did not improve progression-free survival in women with previously untreated human epidermal growth factor receptor-2-positive advanced breast cancer. PFS was increased by 7 months with everolimus therapy in the HR-negative subgroup; however, this did not cross the statistical significance threshold. Increased adverse events were also reported in the everolimus-treated group, as well as on treatment, AE-related deaths.